EUVIMEDEUVIMED entdecken
Crossref

First description of Her2 expression landscape in squamous vulvar cancer

N. F. Pauly, B. Schulz, U. Titze, M. Hanisch-Reitemeier, M. P. Schweiger, N. Majidova, C. Brase, B. Ataseven

Geburtshilfe und Frauenheilkunde · 01.10.2024 · 84 (10) · e197-e198

DOI: 10.1055/s-0044-1790905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.10.2024. Verfasst von N. F. Pauly und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Squamous vulvar cancer (sVC), a rare gynecological malignancy, is experiencing increased incidence due to HPV infections. Currently, surgery and chemoradiation are primary treatments, with no established targeted therapies. Her2 expression has been established as a well-known prognostic and predictive marker in various malignancies.Our study aims to first describe the landscape of Her2 expression in sVC.

Methods

32 consecutive cases of sVC treated at our department between 2019-2024 were included. Her2 testing was performed according to ASCO/CAP Guidelines 2018/2016 for breast and gastric cancer in paraffin-embedded tissue. Immunohistochemistry was conducted as per the IVDR protocol using the VENTANA HER2 (4B5) antibody. The Categories established were Her2 (0): negative, Her2 (1+): ultralow, Her2 (2+/DISH negative): low, Her2 (3+ und 2+/DISH positive): positive. Patient/clinical data were obtained from our tumor database.

Results

32 tumors were analyzed. The median age was 70 years. 22 cases were FIGO IB , three FIGO IA, one FIGO II, four had lymph node involvement (one FIGO IIIA, one FIGO IIIB, two FIGO IIIC). Two patients had metastatic disease at first diagnosis. Twenty-eight tumors showed no Her2 expression (0) classified as Her2 negative. Three tumors exhibited Her2 1+ expression classified as ultralow. One case had no evaluable tumor.

Conclusion

Her2-positivity was not detected in our sVC series. However, the presence of three Her2 1+ tumors suggests the need for further investigation and expansion of the series. This is particularly important for exploring the potential actionability of Her2 ultralow in guiding targeted therapies, with the emergence of antibody-drug conjugates. Publication History Article published online: 01 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Pauly, N. F., Schulz, B., Titze, U., Hanisch-Reitemeier, M., Schweiger, M. P., Majidova, N., Brase, C., & Ataseven, B. (2024). First description of Her2 expression landscape in squamous vulvar cancer. Geburtshilfe und Frauenheilkunde, 84(10), e197-e198. https://doi.org/10.1055/s-0044-1790905

Vancouver

Pauly NF, Schulz B, Titze U, Hanisch-Reitemeier M, Schweiger MP, Majidova N, et al. First description of Her2 expression landscape in squamous vulvar cancer. Geburtshilfe und Frauenheilkunde. 2024;84(10):e197-e198. doi:10.1055/s-0044-1790905

BibTeX
@article{Pauly2024,
  author = {Pauly, N. F. and Schulz, B. and Titze, U. and Hanisch-Reitemeier, M. and Schweiger, M. P. and Majidova, N. and Brase, C. and Ataseven, B.},
  title = {First description of Her2 expression landscape in squamous vulvar cancer},
  journal = {Geburtshilfe und Frauenheilkunde},
  year = {2024},
  volume = {84},
  number = {10},
  pages = {e197--e198},
  doi = {10.1055/s-0044-1790905}
}
Kostenlos starten →